Products for Research Use Only
RegisterLogin

MLN2238

CAT: 0013-GTR19163950-01Size: 1 gDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19163950-01Size:1 g
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
A potent, selective, orally bioavailable proteasome inhibitor with IC50 of 3.4 nM; binds to and inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with Ki of 0.93 nM, weakly inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites (IC50 of 31 and 3,500 n M) ; inhibits growth and induces apoptosis in MM cells; shows improved antitumor activity in models of lymphoma compared with bortezomib.Blood Cancer Approved (In Vitro) :Ixazomib (MLN2238) is an N-capped dipeptidyl leucine boronic acid and preferentially bound to and inhibited the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with an IC50 value of 3.4 nM (Ki of 0.93 nM) . At higher concentrations, Ixazomib (MLN2238) also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites (IC50 of 31 and 3,500 nM, respectively) . Cell viability studies are performed in a variety of mammalian cell lines to compare the in vitro antiproliferative effects of Ixazomib (MLN2238) with Bortezomib. Studies performed with A375 (lung), H460 (lung), HCT-116 (colon), and HT-29 (colon) cells revealed similar LD50 values for the two compounds, which range from 4 to 58 nM. (In Vivo) :Ixazomib (MLN2238) shows antitumor activity in the CWR22 xenograft model. The antitumor effects of Ixazomib (MLN2238) dosed at 14 mg/kg i.v. or 7 mg/kg i.v. are compared with Bortezomib dosed at 0.8 mg/kg i.v. or 0.4 mg/kg i.v. on a twice weekly regimen. The high dose for both Ixazomib (MLN2238) and Bortezomib shows similar antitumor activity in this model (T/C=0.36 and 0.44, respectively) . However, Ixazomib (MLN2238) (7 mg/kg) shows greater efficacy at a 0.5 MTD dose compared with a 0.5 MTD dose of Bortezomib (0.4 mg/kg; T/C=0.49 compared with T/C=0.79, respectively) Ixazomib (MLN2238) shows time-dependent reversible proteasome inhibition; however, the proteasome dissociation half-life (t1/2) for Ixazomib (MLN2238) is determined to be 18 minutes.
CAS Number
1072833-77-2
Product Name Alternative
Ixazomib | MLN 2238 | MLN-2238
Purity
>98% (HPLC)
Solubility
DMSO: ≥ 28 mg/mL
Smiles
CC (C) C[C@@H] (B (O) O) NC (CNC (C1=CC (Cl) =CC=C1Cl) =O) =O
Molecular Formula
C14H19BCl2N2O4
Molecular Weight
361.0287
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Boronic acid, B-[ (1R) -1-[[2-[ (2,5-dichlorobenzoyl) amino]acetyl]amino]-3-methylbutyl]-

Related Products

CatalogName
GTR19172737-01Alisertib (MLN8237)

Alternative Products

CatalogName
A4008-50MLN2238
C16684Ixazomib (MLN2238)
SC0078-5mgIxazeomib (MLN2238)
MBS577775MLN2238(Ixazomib)
A10600-10MLN2238 10mg
A10600-5MLN2238 5mg
bs-75559C-01Ixazomib [MLN2238]
MBS385160-01MLN2238 (Ixazomib)
A10600-100MLN2238 100mg

Popular Products